Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

1. Benralizumab, mepolizumab and omalizumab for treating severe asthma

Benralizumab, mepolizumab and omalizumab for treating severe asthma 1 Driving better decision-making in healthcare Benralizumab, mepolizumab and omalizumab for treating severe asthma Technology Guidance from the MOH Drug Advisory Committee Published on 1 September 2020 Guidance recommendations The Ministry of Health’s Drug Advisory Committee has not recommended listing: • Benralizumab and mepolizumab on the Medication Assistance Fund (MAF) for treating severe eosinophilic asthma (...) ; and • Omalizumab on the MAF for treating severe allergic asthma due to unacceptable cost-effectiveness at the prices proposed by the manufacturers. 2 Driving better decision-making in healthcare Factors considered to inform the recommendations for subsidy Technology evaluation 1.1 1.2 1.3 1.4 The MOH Drug Advisory Committee (“the Committee”) considered the evidence presented for the following technology evaluations in October 2019: a) Benralizumab for treating adults and mepolizumab for treating adults

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

2. Management of Severe Asthma

Management of Severe Asthma Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline | European Respiratory Society Main menu User menu Search Search for this keyword Search for this keyword Management of Severe Asthma: a European Respiratory Society/American Thoracic Society Guideline Fernando Holguin , Juan Carlos Cardet , Kian Fan Chung , Sarah Diver , Diogenes S. Ferreira , Anne Fitzpatrick , Mina Gaga , Liz Kellermeyer , Sandhya Khurana , Shandra (...) Parana, Curitiba, Brazil 6 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia Anne Fitzpatrick 7 Emory University, Division of Pulmonology Allergy/Immunology, Cystic Fibrosis and Sleep, Atlanta, GA, USA Mina Gaga 8 Athens Chest Hospital, Respiratory Medicine Department and Asthma Centre, Athens, Greece Liz Kellermeyer 9 Biomedical Library, National Jewish Health, Denver, CO, USA Sandhya Khurana 10 Pulmonary Diseases and Critical Care, University of Rochester

2020 American Thoracic Society

3. Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report Full Text available with Trip Pro

: Asthma and non-asthmatic eosinophilic bronchitis (NAEB) are among the commonest causes of chronic cough in adults. We sought to determine the role of non-invasive measurements of airway inflammation, including induced sputum and fractional exhaled nitric oxide, in the evaluation of cough associated with asthma, and what the best treatment is for cough due to asthma or NAEB. Methods: We undertook three systematic reviews of randomized controlled trials and observational trials of adults (...) Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get

2020 EvidenceUpdates

4. Travel for people with allergy, asthma and anaphylaxis

Travel for people with allergy, asthma and anaphylaxis ASCIA Travel Plan: Anaphylaxis - Australasian Society of Clinical Immunology and Allergy (ASCIA) | | ASCIA Travel Plan: Anaphylaxis Other travel information for people at risk of anaphylaxis is available from Allergy & Anaphylaxis Australia: Page updated January 2019 Site last updated: 6 Nov 2019 Member Login Remember Me Log in ASCIA Update Information for the community about allergic diseases, immunodeficiencies and other immune diseases

2020 Australasian Society of Clinical Immunology and Allergy

5. Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the Covid-19 pandemic

Addressing therapeutic questions to help Canadian physicians optimize asthma management for their patients during the Covid-19 pandemic 1 ‘In Press’. Submitted for publication in the CJRCCSM on April 7, 2020. POSITION STATEMENT FROM THE CANADIAN THORACIC SOCIETY (CTS) ASTHMA ASSEMBLY STEERING COMMITTEE ADDRESSING THERAPEUTIC QUESTIONS TO HELP CANADIAN PHYSICIANS OPTIMIZE ASTHMA MANAGEMENT FOR THEIR PATIENTS DURING THE COVID-19 PANDEMIC Christopher Licskai a , Connie L. Yang b , Francine M (...) et de Pneumologie de Québec, Laval University, Québec, Québec, Canada; i Deparment of Medicine, Royal Victoria Regional Health Centre, Barrie, Ontario, Canada; j Department of Medicine, Queen’s University, Kingston, Ontario, Canada. Version 1.0 – April 7, 2020 This position statement aims to provide rapid guidance for Canadian physicians treating patients with asthma during the COVID-19 pandemic. The recommendations are informed by a very limited body of direct published data, inference from

2020 Canadian Thoracic Society

6. Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma

Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma CTS Guidance on Salbutamol Shortage – April 13,2020 1 Inhaled Salbutamol Shortage – Mitigation Strategy for Asthma April 13, 2020 Background 1) Health Canada and the pharmaceutical industry have identified that there was a three-fold increase in the demand for salbutamol inhalers in the first 3 weeks of March 2020. 2) This has resulted in a Tier 3 shortage, which by definition is “a situation when a manufacturer/importer is unable (...) and organizations projecting future need and purchasing product in advance of actual need [Stockpiling]. Mitigation Strategy Step 1 Provider communication to patients regarding asthma medication: If you have well controlled asthma, you should not need reliever medication. If you need reliever medication more than three times a week you should speak to your practitioner about ways to improve your asthma control. It is important that you are taking your regular maintenance controller medication as prescribed

2020 Canadian Thoracic Society

7. Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report

Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents: CHEST Guideline and Expert Panel Report Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents CHEST Guideline and Expert Panel Report AndreanneCôté,MD;RichardJ.Russell,MBBS;Louis-PhilippeBoulet,MD;PeterG.Gibson,DMed;KefangLai,MD,PhD; Richard S. Irwin, MD, Master FCCP; and Christopher E. Brightling, PhD; on behalf of the CHEST Expert Cough Panel * BACKGROUND: Asthma and non-asthmatic eosinophilic (...) and areas for future research. CHEST 2020; 158(1):68-96 KEYWORDS: asthma; bronchitis; cough ABBREVIATIONS: FENO= fractionalexhalednitric oxide;NAEB =non- asthmatic eosinophilic bronchitis; RCT = randomized controlled trial AFFILIATIONS: From the Centre de pneumologie (Drs Côté and Boulet), Québec Heart and Lung Institute, Laval University, Québec City, QC, Canada; Department of Respiratory Sciences (Drs Russell and Brightling), Institute for Lung Health, Glen?eld Hospital, Uni- versity of Leicester

2020 American College of Chest Physicians

8. Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma?

Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma? Does Treatment Guided by Exhaled Nitric Oxide Fraction Improve Outcomes in Subgroups of Children With Asthma? - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Eur Respir J Actions . 2020 May 21;55(5):1901879. doi: 10.1183/13993003.01879-2019. Print 2020 May. Does Treatment Guided by Exhaled Nitric Oxide Fraction Improve Outcomes in Subgroups of Children With Asthma? , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Medical Statistics Team, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. 2 Dept of Paediatric Respiratory Medicine

2020 EvidenceUpdates

9. Characteristics of Existing Asthma Self-Management Education Packages

Characteristics of Existing Asthma Self-Management Education Packages Characteristics of Existing Asthma Self-Management Education Packages Technical Brief Number 35 RTechnical Brief Number 35 Characteristics of Existing Asthma Self-Management Education Packages Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2015-00005-I Prepared by: ECRI Institute – Penn Medicine Evidence (...) -based Practice Center Philadelphia, PA Investigators: Brian F. Leas, M.S., M.A. Kelley Tipton, M.P.H. Tyra Bryant-Stephens, M.D. Michelle Jackson-Ware, R.N., B.S.N. Nikhil Mull, M.D. Amy Y. Tsou, M.D., M.Sc. AHRQ Publication No. 20-EHC008 April 2020 ii Key Messages Purpose To identify the components that comprise asthma self-management education (AS-ME) packages used in the United States, and examine, compare, and organize their key characteristics and available research to enable a better

2020 Effective Health Care Program (AHRQ)

10. Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? Full Text available with Trip Pro

adverse events was of low quality, with very few events (10 total) reported overall. Mortality was not reported in any of the studies. There was low statistical heterogeneity between the studies for each of the outcomes reported ( I 2 =0). Commentary Asthma is a chronic respiratory condition that results in constriction of the airways because of inflammation and excess mucus production. Asthmatic patients typically have wheezing caused by narrowed airways, and symptoms are usually controlled (...) Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Access provided by Volume 74, Issue 5, Pages 711–712 Do Antibiotics Improve Outcomes in Patients With Acute Asthma Exacerbations? x Latha Ganti , MD, MBA (EBEM Commentator) , x Javier Rosario , MD (EBEM Commentator) Department

2020 Annals of Emergency Medicine Systematic Review Snapshots

11. Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19

Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19 1 Version 4.0 7/4/20 Advice for Healthcare Professionals Treating People with Asthma (adults) in relation to COVID-19 What can I suggest my patients do to keep themselves healthy? For people with asthma, the best way of staying healthy and recovering if infected with COVID-19 is to ensure their asthma is as stable as possible. This means taking inhaled steroids and other routine medications (...) regularly, as prescribed and detailed in their personal asthma action plan. Having a reliever inhaler is also important if asthma worsens. Ensuring people have had their inhaler technique checked recently is important and you can share this website: https://www.asthma.org.uk/advice/inhaler-videos/ Advise patients to ensure they have a sufficient supply of their medication at home and order them in plenty of time to ensure they do not run out. Emphasise that they do not need to over order/ stock up

2020 British Thoracic Society

12. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Full Text available with Trip Pro

Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Overuse of Short-Acting β 2-agonists in Asthma Is Associated With Increased Risk of Exacerbation and Mortality: A Nationwide Cohort Study of the Global SABINA Programme - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation Eur Respir J Actions . 2020 Apr 16;55(4):1901872. doi: 10.1183/13993003.01872-2019. Print 2020 Apr. Overuse of Short-Acting β 2 -agonists in Asthma Is Associated With Increased Risk of Exacerbation and Mortality: A Nationwide Cohort Study of the Global SABINA Programme , , , , , Affiliations Expand Affiliations 1 Krefting Research Centre, Institute of Medicine, University

2020 EvidenceUpdates

13. Asthma and children: diagnosis and treatment

Asthma and children: diagnosis and treatment Asthma and children: diagnosis and treatment - NPS MedicineWise Log In Menu During the COVID-19 pandemic, you need to continue to take your usual medicines and stay as healthy as possible. Here is some important information for everyone to keep in mind. Featured topics 30 Mar 2020 30 Mar 2020 30 Mar 2020 Featured article Information for consumers about medicines and COVID-19 | Updated regularly as the situation changes. Keep a medicines list The more (...) February 2020 8 January 2020 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Asthma and children: diagnosis and treatment Asthma is a chronic disease that requires accurate diagnosis, regular treatment and review. For consumers , check out Asthma diagnosis and treatment during the COVID

2020 National Prescribing Service Limited (Australia)

14. Budesonide / formoterol fumarate dihydrate - asthma

Budesonide / formoterol fumarate dihydrate - asthma Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. EMA/118969/2020 EMEA/H/C/004882 Budesonide/Formoterol Teva Pharma B.V (...) . (budesonide/ formoterol) An overview of Budesonide/Formoterol Teva Pharma B.V. and why it is authorised in the EU What is Budesonide/Formoterol Teva Pharma B.V. and what is it used for? Budesonide/Formoterol Teva Pharma B.V. is a medicine used for the treatment of asthma in adults for whom a combination product is considered appropriate. It can be used in patients: • whose disease is not adequately controlled by treatment with other asthma medicines called corticosteroids and ‘short-acting beta-2 agonists

2020 European Medicines Agency - EPARs

15. Targeting treatable traits in severe asthma: a randomised controlled trial

Targeting treatable traits in severe asthma: a randomised controlled trial Targeting Treatable Traits in Severe Asthma: A Randomised Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine National Center (...) Mar 5;55(3):1901509. doi: 10.1183/13993003.01509-2019. Print 2020 Mar. Targeting Treatable Traits in Severe Asthma: A Randomised Controlled Trial , , , , , Affiliations Expand Affiliations 1 National Health and Medical Research Council, Centre of Excellence in Severe Asthma, Newcastle, Australia Vanessa.McDonald@newcastle.edu.au. 2 Priority Research Centre for Healthy Lungs, The University of Newcastle, Newcastle, Australia. 3 Hunter Medical Research Institute, Newcastle, Australia. 4 Dept

2020 EvidenceUpdates

16. Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases

Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases Technical Brief Number 34 RTechnical Brief Number 34 Impact of Community Health Worker Certification on Workforce and Service Delivery for Asthma and Other Selected Chronic Diseases Prepared for: Agency for Healthcare Research and Quality (...) -EF March 2020 ii Key Messages Purpose of Technical Brief To explore and describe the state of the evidence on community health worker certification and its relationship with community health worker outcomes (such as recruitment, retention, and employment stability) and outcomes for people with asthma and other selected chronic illnesses. Key messages • A number of States are initiating efforts to certify community health workers practicing in their States. • We did not find any studies evaluating

2020 Effective Health Care Program (AHRQ)

17. Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. (Abstract)

Six-Year Follow-up of a Trial of Antenatal Vitamin D for Asthma Reduction. We previously reported the results of a trial of prenatal vitamin D supplementation to prevent asthma and recurrent wheeze in young children, which suggested that supplementation provided a protective effect at the age of 3 years. We followed the children through the age of 6 years to determine the course of asthma and recurrent wheeze.In this follow-up study, investigators and participants remained unaware (...) of the treatment assignments through the children's sixth birthday. We aimed to determine whether, when maternal levels of 25-hydroxyvitamin D were taken into account, children born to mothers who had received 4400 IU of vitamin D3 per day during pregnancy (vitamin D group) would have a lower incidence of asthma and recurrent wheeze at the age of 6 years than would those born to mothers who had received 400 IU of vitamin D3 per day (control group). Time-to-event methods were used to compare the treatment

2020 NEJM

18. Asthma: School-Based Self-Management Interventions for Children and Adolescents with Asthma

Asthma: School-Based Self-Management Interventions for Children and Adolescents with Asthma Asthma: School-Based Self-Management | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) July 2019 Audience Adolescents and Young Adults Children/Infants Setting School Strategy Case Management Counseling (...) Health Education Organizational Changes This webpage summarizes information available in the CPSTF Finding and Rationale Statement. Asthma: School-Based Self-Management Interventions for Children and Adolescents with Asthma Tabs Snapshot Summary of CPSTF Finding The school-based asthma self-management interventions to reduce hospitalizations and emergency room visits among children and adolescents with asthma. Evidence shows interventions are effective when delivered by trained school staff, nurses

2020 Community Preventive Services Task Force

19. Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. (Abstract)

Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. Asthma is a disease of reversible airflow obstruction characterised clinically by wheezing, shortness of breath, and coughing. Increases in airway type 2 cytokine activity, including interleukin-4 (IL-4), IL-5, and IL-13, are now established biological mechanisms in asthma. Inhaled corticosteroids have been the foundation for asthma treatment, in a large part because they decrease airway type 2 inflammation (...) . However, inhaled or systemic corticosteroids are ineffective treatments in many patients with asthma and few treatment options exist for patients with steroid resistant asthma. Although mechanisms for corticosteroid refractory asthma are likely to be numerous, the development of a new class of biologic agents that target airway type 2 inflammation has provided a new model for treating some patients with corticosteroid refractory asthma. The objective of this Therapeutic paper is to summarise the new

2020 Lancet

20. Using Inhaled Steroids in Asthma durIng the COVID-19 Outbreak Full Text available with Trip Pro

Using Inhaled Steroids in Asthma durIng the COVID-19 Outbreak Inhaled Steroids in Asthma durIng the COVID-19 Outbreak - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Inhaled Steroids in Asthma durIng the COVID-19 Outbreak Jamie Hartmann-Boyce, Richard Hobbs Are inhaled steroids in asthma OK to use or should you discontinue them? Verdict : There is no evidence of a relationship between the use of inhaled (...) corticosteroids and COVID-19 infection at present. Inhaled corticosteroids are generally considered a for controlling asthma symptoms. Evidence from a of seven randomized controlled trials found that discontinuing inhaled corticosteroids in people with stable asthma more than doubled the risk of asthma exacerbation (RR 2.35, 95% CI 1.88 to 2.92, mean follow-up 27 weeks). Inhaled corticosteroids, when taken as prescribed, would reduce the risk of an asthma attack being triggered by a respiratory virus

2020 Oxford COVID-19 Evidence Service